Dianthus Therapeutics
DNTH
92 hedge funds and large institutions have $255M invested in Dianthus Therapeutics in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 8 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
17% more capital invested
Capital invested by funds: $217M → $255M (+$37.8M)
0.07% more ownership
Funds ownership: 4.14% → 4.21% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 94 → 92 (-2)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
72% less call options, than puts
Call options by funds: $46K | Put options by funds: $164K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$9.27M |
| 2 |
JP Morgan Chase
New York
|
+$1.51M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.13M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$960K |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$834K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$9.63M |
| 2 |
Renaissance Technologies
New York
|
-$1.05M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$840K |
| 4 |
Squarepoint
New York
|
-$376K |
| 5 |
UBS AM
Chicago,
Illinois
|
-$368K |
DNTH Hedge Fund Activity: Q4 2020 in Review
92 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q4 2020, worth a combined $255M — up 17% from $217M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of DNTH and 7 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 35 added.
The largest buyer was Aquilo Capital Management, adding an estimated $9.27M. The largest seller was Eventide Asset Management, cutting an estimated $9.63M.
- 92 institutional investors held Dianthus Therapeutics (DNTH) as of Q4 2020, down from 94 in Q3 2020.
- Funds reported $255M of Dianthus Therapeutics stock for Q4 2020, up 17% quarter-over-quarter.
- 7 funds opened new Dianthus Therapeutics positions in Q4 2020 and 8 closed out, a net change of -1 holder.
- The largest Dianthus Therapeutics buyer in Q4 2020 was Aquilo Capital Management, an estimated $9.27M added.
- The largest Dianthus Therapeutics seller in Q4 2020 was Eventide Asset Management, an estimated $9.63M sold.
Based on aggregated 13F filings for Q4 2020.